IP Library Granted Patent US 9,688,679
Granted Patent B2
US 9,688,679 · App. 15/036,210 · Granted Jun 27, 2017

7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,679
App. No.
15/036,210
Granted
Jun 27, 2017
Kind
B2
Abstract

This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): (structurally represented) or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

Claims (7)

1. A method of treatment, comprising administering to a subject in need of such treatment a therapeutic agent comprising compound (1):

or a pharmaceutically acceptable salt thereof, wherein the treatment is for Leukemia.

2. A method of treatment, comprising administering to a subject in need of such treatment a first therapeutic agent comprising compound (1):

or a pharmaceutically acceptable salt thereof, wherein the treatment is for an acute leukemia.

3. The method according to claim 2 , wherein the acute leukemia is selected from group consisting of acute lymphocyte leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, and myeloproliferative disease.

4. A method of treatment comprising administering to a subject having leukemia a pharmaceutically acceptable amount of compound (1):

or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable amount of compound (1) is administered as a salvage therapy.

Assignments (4)
CONFIRMATORY PATENT ASSIGNMENT Recorded Oct 27, 2025
From: CHIMERIX, INC.; ONCOCEUTICS, INC.
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073333/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: POTTORF, RICHARD S.; NALLAGANCHU, BHASKARA RAO; OLSON, GARY
To: PROVID PHARMACEUTICALS INC.
Reel/Frame 041630/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: STOGNIEW, MARTIN; ALLEN, JOSHUA E.
To: ONCOCEUTICS, INC.
Reel/Frame 041631/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: PROVID PHARMACEUTICALS INC.
To: ONCOCEUTICS, INC.
Reel/Frame 041631/0838 →